ART BioScience specializes in the use of novel messenger RNA technologies for the development of therapeutics that may potentially change the course of Duchenne Muscular Dystrophy. The company’s initial work began with lipids licensed from the laboratory of Professor Dan Peer. ART BioScience has optimized these lipids for effective muscle delivery based on a proprietary LNP-based formulation. The delivery system enables the efficient transfer of mRNA to the muscles via systemic administration. The technology reflects years of work scanning numerous lipids and optimizing the formulations for delivery. ART BioScience was founded by Mr. Oren Ozeri and Mr. Alon Hazan, fathers of two children diagnosed with Duchenne Muscular Dystrophy.